GT200900016A - 2-fenilo-indoles como antagonistas del receptor de la prostaglandina d2 - Google Patents
2-fenilo-indoles como antagonistas del receptor de la prostaglandina d2Info
- Publication number
- GT200900016A GT200900016A GT200900016A GT200900016A GT200900016A GT 200900016 A GT200900016 A GT 200900016A GT 200900016 A GT200900016 A GT 200900016A GT 200900016 A GT200900016 A GT 200900016A GT 200900016 A GT200900016 A GT 200900016A
- Authority
- GT
- Guatemala
- Prior art keywords
- phenyl
- criticism
- urban
- compounds
- prostaglandina
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82030206P | 2006-07-25 | 2006-07-25 | |
| US82030106P | 2006-07-25 | 2006-07-25 | |
| US82029906P | 2006-07-25 | 2006-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200900016A true GT200900016A (es) | 2010-10-13 |
Family
ID=38610820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900016A GT200900016A (es) | 2006-07-25 | 2009-01-23 | 2-fenilo-indoles como antagonistas del receptor de la prostaglandina d2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090176804A1 (enExample) |
| EP (1) | EP2066628B1 (enExample) |
| JP (1) | JP2009544721A (enExample) |
| KR (1) | KR20090039735A (enExample) |
| AR (1) | AR062051A1 (enExample) |
| AT (1) | ATE485270T1 (enExample) |
| AU (1) | AU2007276885A1 (enExample) |
| BR (1) | BRPI0714554A2 (enExample) |
| CA (1) | CA2659055A1 (enExample) |
| CL (1) | CL2007002163A1 (enExample) |
| CO (1) | CO6190511A2 (enExample) |
| CR (1) | CR10577A (enExample) |
| DE (1) | DE602007010010D1 (enExample) |
| DK (1) | DK2066628T3 (enExample) |
| EC (1) | ECSP099087A (enExample) |
| GT (1) | GT200900016A (enExample) |
| IL (1) | IL196587A0 (enExample) |
| MA (1) | MA30643B1 (enExample) |
| MX (1) | MX2009000830A (enExample) |
| NO (1) | NO20090862L (enExample) |
| PE (1) | PE20080549A1 (enExample) |
| PT (1) | PT2066628E (enExample) |
| TN (1) | TNSN08515A1 (enExample) |
| TW (1) | TW200821286A (enExample) |
| WO (1) | WO2008014186A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072576A1 (ja) * | 2007-12-04 | 2009-06-11 | Sapporo Breweries Limited | 骨形成促進剤 |
| DK2346819T3 (da) * | 2008-11-17 | 2013-05-13 | Hoffmann La Roche | Naphthyleddikesyre |
| BR112012024114B1 (pt) | 2010-03-22 | 2021-02-09 | Idorsia Pharmaceuticals Ltd | Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| EP2912458B1 (en) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| TWI649321B (zh) | 2014-03-17 | 2019-02-01 | 瑞士商愛杜西亞製藥有限公司 | 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途 |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| AU2016323262B2 (en) | 2015-09-15 | 2020-11-19 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| JP2020533595A (ja) | 2017-09-13 | 2020-11-19 | プロジェニティ， インコーポレイテッド | 子癇前症バイオマーカならびに関連するシステムおよび方法 |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP3759073A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| JP7455762B2 (ja) * | 2018-05-09 | 2024-03-26 | グルソックス・バイオテック・アーベー | 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN111333516B (zh) * | 2020-04-14 | 2022-09-06 | 国药集团化学试剂有限公司 | 一种2-氯-5-溴硝基苯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
-
2007
- 2007-07-20 AU AU2007276885A patent/AU2007276885A1/en not_active Abandoned
- 2007-07-20 PT PT07799729T patent/PT2066628E/pt unknown
- 2007-07-20 DE DE602007010010T patent/DE602007010010D1/de active Active
- 2007-07-20 CA CA002659055A patent/CA2659055A1/en not_active Abandoned
- 2007-07-20 MX MX2009000830A patent/MX2009000830A/es active IP Right Grant
- 2007-07-20 EP EP07799729A patent/EP2066628B1/en active Active
- 2007-07-20 BR BRPI0714554-3A patent/BRPI0714554A2/pt not_active IP Right Cessation
- 2007-07-20 DK DK07799729.4T patent/DK2066628T3/da active
- 2007-07-20 JP JP2009521914A patent/JP2009544721A/ja not_active Abandoned
- 2007-07-20 WO PCT/US2007/073945 patent/WO2008014186A1/en not_active Ceased
- 2007-07-20 AT AT07799729T patent/ATE485270T1/de active
- 2007-07-20 KR KR1020097001687A patent/KR20090039735A/ko not_active Abandoned
- 2007-07-23 PE PE2007000951A patent/PE20080549A1/es not_active Application Discontinuation
- 2007-07-24 AR ARP070103291A patent/AR062051A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702163A patent/CL2007002163A1/es unknown
- 2007-07-25 TW TW096127005A patent/TW200821286A/zh unknown
-
2008
- 2008-12-12 TN TNP2008000515A patent/TNSN08515A1/en unknown
-
2009
- 2009-01-15 CO CO09002745A patent/CO6190511A2/es not_active Application Discontinuation
- 2009-01-19 IL IL196587A patent/IL196587A0/en unknown
- 2009-01-21 CR CR10577A patent/CR10577A/es not_active Application Discontinuation
- 2009-01-22 US US12/357,725 patent/US20090176804A1/en not_active Abandoned
- 2009-01-23 GT GT200900016A patent/GT200900016A/es unknown
- 2009-01-23 EC EC2009009087A patent/ECSP099087A/es unknown
- 2009-02-13 MA MA31635A patent/MA30643B1/fr unknown
- 2009-02-24 NO NO20090862A patent/NO20090862L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE485270T1 (de) | 2010-11-15 |
| DE602007010010D1 (de) | 2010-12-02 |
| CL2007002163A1 (es) | 2008-02-08 |
| MX2009000830A (es) | 2009-02-03 |
| DK2066628T3 (da) | 2011-02-07 |
| IL196587A0 (en) | 2009-11-18 |
| US20090176804A1 (en) | 2009-07-09 |
| CO6190511A2 (es) | 2010-08-19 |
| CR10577A (es) | 2009-03-20 |
| WO2008014186A1 (en) | 2008-01-31 |
| TW200821286A (en) | 2008-05-16 |
| EP2066628B1 (en) | 2010-10-20 |
| AU2007276885A1 (en) | 2008-01-31 |
| PT2066628E (pt) | 2010-12-31 |
| TNSN08515A1 (en) | 2010-04-14 |
| KR20090039735A (ko) | 2009-04-22 |
| PE20080549A1 (es) | 2008-06-20 |
| ECSP099087A (es) | 2009-02-27 |
| AR062051A1 (es) | 2008-08-10 |
| MA30643B1 (fr) | 2009-08-03 |
| JP2009544721A (ja) | 2009-12-17 |
| EP2066628A1 (en) | 2009-06-10 |
| CA2659055A1 (en) | 2008-01-31 |
| BRPI0714554A2 (pt) | 2013-05-07 |
| NO20090862L (no) | 2009-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200900016A (es) | 2-fenilo-indoles como antagonistas del receptor de la prostaglandina d2 | |
| UY30917A1 (es) | Moduladores 2-aminopiridina del receptor histamina h | |
| CL2014001664A1 (es) | Compuestos derivados de 2-([1,4]dioxan-2-ilmetoxi)-6,7-dihidropirimido[6,1-a]isoquinolin-4-ona, antagonistas del receptor gpr84; composicion farmaceutica; metodo de tratamiento o profilaxis; y uso en el tratamiento o profilaxis de afecciones inflamatorias tales como artritis reumatoide, vasculitis, asma y psoriasis, entre otras. | |
| CR20130643A (es) | Combinación que comprende umeclidinio y un corticosteroide | |
| NI201300043A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| CL2007003755A1 (es) | Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe | |
| CR20120331A (es) | Aminopirimidinas como inhibidores de syk | |
| UY30479A1 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4 | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| ECSP11011163A (es) | Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC | |
| MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
| CL2016002888A1 (es) | Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras. | |
| ECSP12012010A (es) | Nuevos antagonistas del receptor CCR2 y usos de los mismos. | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| CR20110509A (es) | Composicion farmaceutica | |
| CO6541545A2 (es) | Compuestos de espiropiperidina como antagonistas del receptor orl-1 | |
| CR20140405A (es) | Apoptosis señal reguladores del inhibidor de quinasa | |
| UY32629A (es) | Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c. | |
| ECSP088807A (es) | Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1) | |
| NI201000214A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4. | |
| ECSP12011980A (es) | Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana. | |
| CL2009000750A1 (es) | Compuestos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona; composicion farmaceutica; y su uso para el tratamiento o profilaxis de trastornos neurodegenerativos, trastornos ateroscleroticos cardio y cerebrovasculares, artritis reumatoide y enfermedades pulmonares como epoc, asma o dolor. | |
| TN2011000653A1 (en) | Pharmaceutical compositions and solid forms | |
| CL2008002827A1 (es) | Compuestos derivados de 2-s-bencil pirimidina, antagonistas del receptor crth2; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades alergicas mediadas por eosinofilos y basofilos, tales como asma, rinitis alergica, dermatitis atopica, conjuntivitis alergica, sinusitis y psoriasis, entre otras | |
| CU20150164A7 (es) | Benzoxazoles sustituidos |